Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is expected to post its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Tango Therapeutics to post earnings of ($0.34) per share and revenue of $8.02 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $7.84 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Trading Down 4.7 %

TNGX stock opened at $2.01 on Monday. The firm’s 50-day moving average is $2.75 and its two-hundred day moving average is $4.99. The company has a market capitalization of $217.30 million, a price-to-earnings ratio of -1.70 and a beta of 0.87. Tango Therapeutics has a 52 week low of $1.78 and a 52 week high of $12.02.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. B. Riley lowered their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research report on Thursday, December 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $12.33.

Insider Activity at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 24,268 shares of company stock valued at $72,561. Corporate insiders own 6.30% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.